Keryx kidney disease drug meets late-stage trial goal

[riky]

Keryx kidney disease drug meets late-stage trial goal

(Reuters) - Keryx Biopharmaceuticals Inc said a late-stage trial of its experimental drug for kidney disease met the main study goal of reducing phosphate levels in blood, sending the company's shares up as much as 49 percent. The level of phosphate in blood increases when kidney function declines. Keryx is testing Zerenex as a treatment for elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis. The drug showed a statistically significant reduction in patients' blood phosphate level compared with a placebo over a four-week period. ...

Source: You are not allowed to view links. Register or Login